Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Niaspan · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm A | EXPERIMENTAL | Arm A will receive a Niaspan treatment in Period 1 and Placebo treatment in Period 2 |
| Arm B | EXPERIMENTAL | Arm B will receive a Placebo treatment in Period 1 and Niaspan treatment in Period 2 |
| 1 | EXPERIMENTAL | Niaspan - Placebo |
| 2 | EXPERIMENTAL | Placebo - Niaspan |
| Name | Type | Description |
|---|---|---|
| Niaspan | DRUG | Niaspan™ |
| Comparator: Placebo | DRUG | Placebo |
Inclusion Criteria: * Healthy Male Subjects Exclusion Criteria : * Subject has a history of stroke, chronic seizures, or major neurological disorder * Subject has a history of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respira...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Eli Lilly and Company | LLY | 2 | PHASE3 | Lepodisiran |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Enlicitide, Rosuvastatin |
| NewAmsterdam Pharma Company N.V. | NAMS | 3 | PHASE3 | obicetrapib, ezetimibe daily |
| AstraZeneca PLC | AZN | 3 | PHASE2 | AZD0780, Rosuvastatin |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1 | PHASE1 | ARO-DIMERPA |
| Novartis AG Sponsored ADR | NVS | 1 | - | Undisclosed |
| CRISPR Therapeutics AG | CRSP | 1 | PHASE1 | CTX310 |
| HeartFlow, Inc. | HTFL | 1 | N/A | Rosuvastatin |
Niaspan is a small molecule being studied for the treatment of dyslipidemia, a condition characterized by abnormal levels of lipids in the blood. It is being developed by Merck & Company, Inc. (MRK) and is currently in Phase 1 clinical development.
Niaspan is a small molecule being investigated for dyslipidemia. Its specific molecular target has not been disclosed in the available clinical trial information. The drug is being studied for its effects on lipid levels, including high-density lipoprotein (HDL).
Niaspan is being developed by Merck & Company, Inc., which trades under the ticker symbol MRK. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with dyslipidemia.
Niaspan is in Phase 1 clinical development. Two Phase 1 trials have been completed, with a total enrollment of 49 participants. The drug is investigational and has not been approved by regulatory authorities.
Niaspan has been studied in two completed Phase 1 clinical trials. NCT01071291 evaluated its effects on high-density lipoprotein in healthy male subjects, and NCT01104519 examined its impact on vascular reactivity. Both trials were controlled and double-blind.
Niaspan is a formulation of niacin, also known as vitamin B3, used to treat lipid disorders. In clinical trials, it is being studied for dyslipidemia. The drug is being developed by Merck & Company, Inc. (MRK) and is currently in Phase 1 development.